Gilenya is the first multiple sclerosis drug approved for children
Multiple Sclerosis Guidelines: AAN's Recommendations for Initiating, Switching, Stopping Disease-Modifying TherapyApril 26, 2018
The new guidelines focus on helping clinicians decide when to initiate, switch, or discontinue disease-modifying therapies for multiple sclerosis.
Investigators believe the siponimod EXPAND study is the first trial of disease-modifying therapy to show superiority over a placebo for disability progression in SPMS.
The FDA approved Ocrevus to treat adults with primary progressive multiple sclerosis and relapsing forms of the disease.
Younger age, relapsing forms of MS, fewer prior immunotherapy treatments, and lower baseline EDSS score were factors associated with better outcomes for stem cell transplantation.
Patients who regularly drank at least four cups of coffee a day were one-third less likely to have MS, compared with people who avoided coffee.
In primary and secondary analyses, vaccination was not associated with an increased risk of multiple sclerosis or other demyelinating diseases.
Patients with multiple sclerosis who had high levels of sodium intake were 3.4 times more likely to develop a new lesion.
The American Academy of Neurology has issued new evidence-based complementary and alternative medicine guidelines for multiple sclerosis.
A European patient with multiple sclerosis developed progressive multifocal leukoencephalopathy after taking the drug fingolimod.
Dimethyl fumarate is the third oral medication available to treat multiple sclerosis.
Combining interferon beta-1a and glatiramer acetate therapy does not provide added clinical benefit to patients with multiple sclerosis.
Diffusion tension imaging shows differences between cognitively preserved vs. impaired multiple sclerosis.
Thinning of the ganglion cell/inner plexiform of the retina may be a useful measure of the efficacy of novel MS therapies in future clinical trials.
Vitamin D may act as a protective factor for MS somewhere between late pregnancy and young adulthood, but no association for in utero exposure.
Two phase 3 studies show benefit with alemtuzumab as first-line therapy and for both nonrefractory and refractory MS.
In relapsing-remitting MS, disease activity after treatment with interferon (IFN)β-1a linked to poor long-term outcomes.